Business Context and Reporting Period
Company: Regeneron Pharmaceuticals, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2001
Business Overview: Regeneron is a biopharmaceutical company focused on discovering, developing, and commercializing therapeutic drugs for serious medical conditions. The company has not yet generated sales or profits from the commercialization of its product candidates. Its strategy relies on proprietary technology platforms and collaborations with partners such as Procter & Gamble, Amgen, and Merck.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended Sep 30, 2001 | Nine Months Ended Sep 30, 2001 |
|---|---|---|
| Total Revenues | $5,480 | $17,572 |
| Net Loss | ($19,931) | ($47,802) |
| Net Loss Per Share (Basic/Diluted) | ($0.46) | ($1.15) |
| Operating Expenses | $28,774 | $73,662 |
| Research & Development Expenses | $25,039 | $61,440 |
| Cash and Cash Equivalents (Sep 30, 2001) | $99,974 | |
| Marketable Securities (Sep 30, 2001) | $168,054 (Current + Non-Current) | |
| Total Assets (Sep 30, 2001) | $318,613 | |
| Accumulated Deficit (Sep 30, 2001) | ($271,320) |
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased significantly to $5.5 million for the quarter (from $15.0 million in Q3 2000) and $17.6 million for the nine-month period (from $40.1 million in 2000). This was driven by a reduction in contract research and development revenue from Procter & Gamble (dropping to $2.5 million per quarter from ~$6.8 million) and the cessation of clinical trial activity for BDNF in the Amgen-Regeneron partnership.
- Expense Increase: Operating expenses rose to $28.8 million for the quarter (from $19.5 million) and $73.7 million for the nine months (from $55.6 million). Research and development expenses increased due to higher staffing and the initiation of a Phase III clinical program for AXOKINE (obesity treatment).
- Widening Loss: Net loss expanded to $19.9 million for the quarter (from $3.1 million) and $47.8 million for the nine months (from $14.8 million).
- Investment Income: Investment income increased to $3.2 million for the quarter and $9.5 million for the nine months, primarily due to interest earned on proceeds from a public offering in March 2001.
Guidance, Outlook, and Risks
Outlook and Capital Resources: Regeneron expects operating losses to continue and be substantial for at least the next several years. The company anticipates that existing capital resources will fund operations through at least 2003. Approximately 50-70% of expenditures are expected to be directed toward preclinical and clinical development of product candidates (including AXOKINE, IL-1 Trap, and VEGF Trap).
Recent Financing Activities:
- Equity: In March 2001, the company completed a public offering of 6.5 million shares at $25.00 per share, netting approximately $153.6 million.
- Debt: In October 2001 (subsequent to the period end), the company issued $200 million in convertible senior subordinated notes due 2008, receiving approximately $193.4 million in proceeds.
- Debt Repayment: In October 2001, the company paid off a remaining $1.5 million note payable to the New York State Urban Development Corporation.
Risks and Contingencies:
- Clinical Trial Risks: Success is not guaranteed; delays or failures in clinical trials (e.g., AXOKINE, Cytokine Traps) could materially adversely affect the company.
- Collaboration Dependence: Termination of agreements with partners like Procter & Gamble or Amgen could result in a loss of funding.
- Intellectual Property: The company faces a patent opposition from Immunex Corporation regarding its Cytokine Traps patent in Europe.
- Immune Response: Recombinant protein therapies may trigger antibody responses in patients, potentially neutralizing the drug's effectiveness.
Investor Verification Checklist
- Cash Burn Rate: Verify the sustainability of the $268 million cash position against the projected $73.7 million operating expense run rate for the nine-month period.
- AXOKINE Phase III Progress: Monitor enrollment and preliminary data from the pivotal Phase III obesity trial initiated in July 2001, which is critical for future revenue potential.
- Convertible Note Terms: Review the specific redemption triggers and conversion price ($30.25) of the $200 million notes issued in October 2001 to assess potential future dilution.
- Procter & Gamble Agreement: Confirm the stability of the $2.5 million quarterly research support from P&G through 2005.
- Patent Litigation: Track the status of the European Patent Office opposition filed by Immunex Corporation regarding Cytokine Traps.